Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Elan dumps Alkermes shares in 'orderly' race to the exit

This article was originally published in Scrip

Executive Summary

Elan has raised $381 million through the sale of 76% of its shares in Alkermes. Elan acquired 31.9 million shares in the new Alkermes and was granted $500 million in cash when it merged its formulation and manufacturing business Elan Drug Technology (EDT) with Alkermes in September 2011 (scripintelligence.com, 19 July 2011). That deal was valued at about $1 billion at closing, implying that Elan has realised neither gain nor loss on its latest transaction.

Advertisement

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC016617

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel